Merck Serono combines its drugs for treating diabetes, cardiovascular diseases and thyroid disorders in one therapeutic area: CardioMetabolic Care. In recent years, interrelationships between cardiovascular diseases, diabetes and thyroid disorders have been recognized and documented. Merck Serono offers doctors and patients the opportunity to treat the often complex symptoms more effectively by taking an integrated approach to disease management.

Diabetes and heart disease are closely linked; studies show that diabetes is frequently combined with other cardiovascular risk factors such as high blood pressure, obesity and lipid disorders, a clustering of risk factors known as metabolic syndrome. Thyroid disorders are closely associated with both diabetes and cardiovascular disease. In patients with type 2 diabetes, thyroid disorders are two-to-five times more frequent than among the general population. Heart muscle cells contain receptors for thyroid hormones, so cardiac function is influenced by too many or too few thyroid hormones.

Cardiovascular diseases continue to be the most frequent cause of death in industrialized countries. Merck Serono offers an extensive range of therapeutic options to treat these conditions with the Concor® product family of the beta-blocker bisoprolol. Another focus is on drugs for the treatment of glucose metabolism and thyroid disorders. Merck Serono is among the leading manufacturers of oral antidiabetic agents for the treatment of type 2 diabetes, formerly referred to as “adult-onset diabetes”. More than six million patients worldwide benefit from the various products of the Glucophage® franchise.

More about: